Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

B cell targeted therapies: safety considerations.

Arthur F Kavanaugh1

  • 1Center for Innovative Therapy, University of California San Diego, San Diego, California 92093-0943, USA. akavanaugh@ucsd.edu

The Journal of Rheumatology. Supplement
|May 3, 2006
PubMed
Summary

B cell targeted therapies show promise for rheumatic diseases, with rituximab having the most data. Long-term safety and effects on immunity require further investigation in clinical trials and registries.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.

RMD open·2018
Same author

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.

RMD open·2017
Same author

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.

RMD open·2016
Same author

GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting.

The Journal of rheumatology·2014
Same author

The problem of choice: current biologic agents and future prospects in RA.

Nature reviews. Rheumatology·2013
Same author

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.

Dermatology and therapy·2012

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • B cell targeted therapies are emerging treatments for rheumatic diseases.
  • Rituximab, an anti-CD20 monoclonal antibody, has the most extensive data among these therapies.
  • Various B cell therapies exist with distinct mechanisms, potentially leading to different efficacy and safety profiles.

Purpose of the Study:

  • To review the current understanding of B cell targeted therapies in rheumatic diseases.
  • To highlight the existing data on rituximab's effectiveness and safety.
  • To identify key questions regarding the long-term safety and use of these therapies.

Main Methods:

  • Review of clinical trial data for B cell targeted therapies.
  • Analysis of safety data for rituximab in oncology and rheumatoid arthritis (RA) trials.
  • Discussion of ongoing research and data collection needs.

Main Results:

  • Rituximab has the most substantial clinical trial data for B cell therapy in rheumatic diseases.
  • Concerns exist regarding the impact of B cell depletion on humoral immunity.
  • Phase II trials are beginning to assess rituximab's safety specifically in RA patients.

Conclusions:

  • While B cell therapies show potential, long-term safety, especially with repeated courses or combination treatments, needs clarification.
  • Ongoing clinical trials, registries, and long-term patient follow-up are crucial for understanding safety profiles.
  • Further research is needed to fully elucidate the long-term implications of B cell targeted therapies in rheumatic disease management.

Related Experiment Videos